Your session is about to expire
← Back to Search
NMES for Heart Failure (NeuHFRecover Trial)
N/A
Waitlist Available
Research Sponsored by University of Vermont Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up hospital discharge (within 1 day) and 4-weeks post-discharge
Awards & highlights
NeuHFRecover Trial Summary
This trial is testing whether a 4-week at-home exercise program can help improve or preserve physical function for those who have been hospitalized for HFpEF.
Who is the study for?
This trial is for individuals aged 50-90 with a clinical diagnosis of HFpEF (a type of heart failure) who are being treated in the hospital and live within 30 miles of the medical center. They must be able to give informed consent. People with severe inflammatory diseases, certain cancers, advanced dementia, exercise-limiting conditions, extreme obesity, or specific cardiovascular implants cannot participate.Check my eligibility
What is being tested?
The study is testing if an at-home exercise program using neuromuscular electrical stimulation (NMES), started after hospitalization for HFpEF and continued for four weeks post-discharge, can help maintain or improve physical function.See study design
What are the potential side effects?
While not explicitly stated here, NMES may cause skin irritation where electrodes are placed, muscle fatigue from contractions induced by the device and discomfort during use.
NeuHFRecover Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from hospital discharge (within 1 day) to 4-weeks post-discharge
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from hospital discharge (within 1 day) to 4-weeks post-discharge
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
6 Minute Walk Distance (6MW)
Secondary outcome measures
Katz Index of Independence in Activities of Daily Living
Lawton Instrumental Activities of Daily Living (IADL) Scale
Medical Outcome Short Form 36 - Role Physical
+8 moreSide effects data
From 2019 Phase 1 & 2 trial • 25 Patients • NCT029455539%
Re-injury of ACL (graft failure)
9%
Re-injury of meniscus
100%
80%
60%
40%
20%
0%
Study treatment Arm
Microstimulation
Neuromuscular Electrical Stimlulation
NeuHFRecover Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Neuromuscular electrical stimulationExperimental Treatment1 Intervention
Neuromuscular electrical stimulation of the quadriceps. 45 minutes, 5 days per week
Group II: ControlActive Control1 Intervention
No treatment control
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Neuromuscular electrical stimulation
2014
Completed Phase 2
~850
Find a Location
Who is running the clinical trial?
University of Vermont Medical CenterLead Sponsor
41 Previous Clinical Trials
25,765 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a condition that affects your muscles or nerves because of a stroke or other brain-related event.You have a body mass index (BMI) of 40 or higher.You have a blood clot in your legs or a device in your chest to help with your heart's rhythm.You are between 50 and 90 years old.You have been diagnosed with heart failure with preserved ejection fraction (HFpEF) and are currently being treated in the hospital.You have rheumatoid arthritis or another inflammatory or autoimmune disease.You have any type of cancer except for non-melanoma skin cancer or low-grade prostate cancer.You have serious memory problems like severe dementia or Alzheimer's disease.You have a condition that limits your ability to exercise due to problems with your blood vessels.
Research Study Groups:
This trial has the following groups:- Group 1: Control
- Group 2: Neuromuscular electrical stimulation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this research endeavor include individuals aged 30 and above?
"The cut-off age for this trial is 90 years old, with a minimum participant age of 50. This study only has 22 studies that include patients below 18, and 692 including individuals over 65."
Answered by AI
Are there still slots available for volunteers to participate in this research?
"According to the information found on clinicaltrials.gov, this medical trial is recruiting participants at present; it was initially posted on February 7th 2022 and has most recently been updated April 13th of the same year."
Answered by AI
Am I eligible to join this clinical trial?
"This clinical trial seeks 60 participants with heart failure and aged between 50 to 90 years old."
Answered by AI
How many participants have been recruited for the clinical experiment?
"Affirmative. Clinicaltrials.gov states that this clinical trial is presently enlisting patients, with the initial posting having been on February 7th 2022 and the latest update occurring April 13th 2022. This medical study aims to recruit a total of 60 subjects at one single site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger